头颈鳞癌患者源性类器官模型的建立和鉴定

doi:10.19438/j.cjoms.2022.04.003

中国口腔颌面外科杂志 ›› 2022, Vol. 20 ›› Issue (4): 328-333.doi: 10.19438/j.cjoms.2022.04.003

头颈鳞癌患者源性类器官模型的建立和鉴定

汪冲, 康馨丹, 王瑞, 吴亚平, 孙露露, 张志愿, 孙树洋

上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,上海交通大学口腔医学院, 国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011

收稿日期:2021-12-21 修回日期:2022-04-17 出版日期:2022-07-20 发布日期:2022-07-20
通讯作者: 孙树洋,E-mail: sunshuyang@sjtu.edu.cn
作者简介:汪冲（1996-）,男,硕士研究生,E-mail: wangchongkq@sjtu.edu.cn
基金资助:
国家自然科学基金面上项目（81872199）; 国家重点研发计划（2017YFC0908500）; 国家自然科学基金重点项目（82030085）

Establishment and identification of patient-derived organoid model in head and neck squamous carcinoma

WANG Chong, KANG Xin-dan, WANG Rui, WU Ya-ping, SUN Lu-lu, ZHANG Zhi-yuan, SUN Shu-yang

Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011,China

Received:2021-12-21 Revised:2022-04-17 Online:2022-07-20 Published:2022-07-20

摘要/Abstract

摘要： 目的: 构建及鉴定头颈鳞癌（head and neck squamous cell carcinoma, HNSCC）患者源性类器官（patient-derived organoid, PDO）模型。方法: 通过HNSCC样本分离肿瘤细胞,于基质胶中三维培养和传代,定时记录模型生长情况。利用H-E染色观察PDO模型与患者肿瘤组织的组织病理学形态,同时利用免疫组织化学染色检测HNSCC标志物CKH、P63、SMA和Ki67在两者间的表达情况,评估PDO模型与患者肿瘤组织间的符合程度。结果: 本研究建立3例能稳定传代的PDO模型,组织病理学及4个肿瘤标志物鉴定结果显示模型与患者组织间一致性较高。结论: 以HNSCC样本构建的PDO模型能够反映患者的组织形态学和生物标志物特征,可作为今后HNSCC研究中可靠的临床前模型。

关键词: 头颈鳞癌, 患者源性类器官模型, 临床前模型

Abstract: PURPOSE: To construct and identify patient-derived organoid (PDO) model of head and neck squamous cell carcinoma(HNSCC). METHODS: Tumor cells, isolated from HNSCC samples, were cultured and passaged in matrix gel with three dimensions. The growth was also recorded at regular intervals. The correlation between patient tumor tissue and PDO models in histopathological and tumor molecular markers was compared using H-E and immunohistochemical staining assay. RESULTS: This study displayed 3 cases of PDO models that could be passaged stably, and the histopathology and tumor marker identification results showed that the model and the patient's tissues were consistent with each other. CONCLUSIONS: The PDO model constructed from samples of HNSCC could reflect the patient's histomorphology and biomarker characteristics, and could be utilized as a reliable preclinical model in the further HNSCC study.

Key words: Head and neck squamous cell carcinoma, Patient-derived organoid, Preclinical model

中图分类号:

R739.8

汪冲, 康馨丹, 王瑞, 吴亚平, 孙露露, 张志愿, 孙树洋. 头颈鳞癌患者源性类器官模型的建立和鉴定[J]. 中国口腔颌面外科杂志, 2022, 20(4): 328-333.

WANG Chong, KANG Xin-dan, WANG Rui, WU Ya-ping, SUN Lu-lu, ZHANG Zhi-yuan, SUN Shu-yang. Establishment and identification of patient-derived organoid model in head and neck squamous carcinoma[J]. China J Oral Maxillofac Surg, 2022, 20(4): 328-333.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Chen W, Zheng R, Baade P D, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Rajasagi M, Shukla SA, Fritsch EF, et al.Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia[J]. Blood, 2014, 124(3): 453-462.
[4] Chow LQM.Head and neck cancer[J]. N Engl J Med, 2020, 382(1): 60-72.
[5] Ferris RL, Blumenschein G, Fayette J, et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016, 375(19): 1856-1867.
[6] Haddad RI, Shin DM.Recent advances in head and neck cancer[J]. N Engl J Med, 2008, 359(11): 1143-1154.
[7] Cramer JD, Burtness B, Le QT, et al.The changing therapeutic landscape of head and neck cancer[J]. Nat Rev Clin Oncol, 2019, 16(11): 669-683.
[8] Souza AG, Silva IBB, Campos-Fernandez E, et al.Comparative assay of 2D and 3D cell culture models: proliferation, gene expression and anticancer drug response[J]. Curr Pharm Des, 2018, 24(15): 1689-1694.
[9] Friedrich J, Seidel C, Ebner R, et al.Spheroid-based drug screen: considerations and practical approach[J]. Nat Prot, 2009, 4(3): 309-324.
[10] Howes AL, Chiang GG, Lang ES, et al.The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures[J]. Mol Cancer Ther, 2007, 6(9): 2505-2514.
[11] Hidalgo M, Amant F, Biankin AV, et al.Patient-derived xenograft models: an emerging platform for translational cancer research[J]. Cancer Discov, 2014, 4(9): 998-1013.
[12] Stewart EL, Mascaux C, Pham NA, et al.Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma[J]. J Clin Oncol, 2015, 33(22): 2472-2480.
[13] Gao H, Korn J, Ferretti S, et al.High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response[J]. Nat Med, 2015, 21(11): 1318-1325.
[14] Palechor-Ceron N, Krawczyk E, Dakic A, et al.Conditional reprogramming for patient-derived cancer models and next-generation living biobanks[J]. Cells, 2019, 8(11): 1327-1351.
[15] Rossi G, Manfrin A, Lutolf MP.Progress and potential in organoid research[J]. Nat Rev Genet, 2018, 19(11): 671-687.
[16] Drost J, Clevers H.Organoids in cancer research[J]. Nat Rev Cancer, 2018, 18(7): 407-418.
[17] Lancaster MA, Knoblich JA.Organogenesis in a dish: modeling development and disease using organoid technologies[J]. Science, 2014, 345(6194): 1247125.
[18] Driehuis E, Kolders S, Spelier S, et al.Oral mucosal organoids as a potential platform for personalized cancer therapy[J]. Cancer Discov, 2019, 9(7): 852-871.
[19] Tanaka N, Osman AA, Takahashi Y, et al.Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity[J]. Oral Oncol, 2018, 87: 49-57.
[20] Bartfeld S, Bayram T, Van De Wetering M, et al. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection[J]. Gastroenterology, 2015, 148(1):126-136.e6.
[21] Scanu T, Spaapen RM, Bakker JM, et al.Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma[J]. Cell Host Microbe, 2015, 17(6): 763-774.
[22] Dijkstra KK, Cattaneo CM, Weeber F, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids [J]. Cell, 2018, 174(6): 1586-1598.e12.
[23] Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment [J]. Cell, 2018, 175(7): 1972-1988.e16.
[24] Torre L, Bray F, Siegel R, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[25] Mroz EA, Tward AD, Pickering CR, et al.High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma[J]. Cancer, 2013, 119(16): 3034-3042.
[26] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南[M]. 北京: 人民卫生出版社, 2021.
Guideline Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of head and neck tumors[M]. Beijing: People's Medical Publishing House,2021.
[27] Burtness B, Harrington K, Greil R, et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet (London, England), 2019, 394(10212): 1915-1928.

头颈鳞癌患者源性类器官模型的建立和鉴定

Establishment and identification of patient-derived organoid model in head and neck squamous carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	高嘉敏, 姚艳丽, 王玉珏, 张志愿, 孙树洋. 多西他赛对头颈鳞癌细胞焦亡的影响及作用机制探讨[J]. 中国口腔颌面外科杂志, 2023, 21(2): 105-111.
[2]	陈澜, 张志愿, 孙树洋. 从“合成致死”策略的视角浅谈头颈鳞癌靶向治疗[J]. 中国口腔颌面外科杂志, 2021, 19(3): 278-283.
[3]	常涵月, 马海龙, 杨溪, 张志愿. 丙酮酸激酶M2与CD276在头颈鳞癌中的表达及临床意义[J]. 中国口腔颌面外科杂志, 2020, 18(4): 297-301.
[4]	张旭;方其根;李振宁;刘法昱;孙长伏. 裸鼠皮下种植性人头颈鳞癌模型的建立 [J]. 中国口腔颌面外科杂志, 2013, 11(5): 395-398.
[5]	郭伟;任国欣;李朝军;吴云腾;张陈平;孙坚;张志愿;邱蔚六. 晚期口腔颌面-头颈鳞癌EGFR单抗靶向治疗—71例临床分析 [J]. 中国口腔颌面外科杂志, 2013, 11(2): 128-130.